0001127602-24-020270.txt : 20240710
0001127602-24-020270.hdr.sgml : 20240710
20240710120448
ACCESSION NUMBER: 0001127602-24-020270
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240708
FILED AS OF DATE: 20240710
DATE AS OF CHANGE: 20240710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farrell Michael J.
CENTRAL INDEX KEY: 0001485164
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15317
FILM NUMBER: 241109278
MAIL ADDRESS:
STREET 1: C/O REMED INC
STREET 2: 9001 SPECTRUM CTR. BLVD.
CITY: SAN DIEGO,
STATE: CA
ZIP: 92123
FORMER NAME:
FORMER CONFORMED NAME: Farrell Michael
DATE OF NAME CHANGE: 20100224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RESMED INC
CENTRAL INDEX KEY: 0000943819
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 980152841
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 9001 SPECTRUM CENTER BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
BUSINESS PHONE: 8587462400
MAIL ADDRESS:
STREET 1: 9001 SPECTRUM CENTER BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92123
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-07-08
0000943819
RESMED INC
RMD
0001485164
Farrell Michael J.
RESMED INC.
9001 SPECTRUM CENTER BLVD
SAN DIEGO
CA
92123
1
Chief Executive Officer
1
ResMed Common Stock
2024-07-08
4
M
0
14683
84.98
A
455482
D
ResMed Common Stock
2024-07-08
4
S
0
14683
192.9667
D
440799
D
ResMed Common Stock
0
I
Lisette and Michael Farrell Foundation
ResMed Common Stock
4090
I
Lisette and Michael Farrell Family Trust
ResMed Common Stock Options
84.98
2024-07-08
4
M
0
14683
0
D
2018-11-11
2024-11-16
ResMed Common Stock
14683
58732
D
The transaction was conducted under a Rule 10b5-1 plan adopted January 31, 2024.
This transaction was executed in multiple trades at prices ranging from $192.03 - $194.73. The price reported above reflects the weighted average sale price.
Represents date options first became exercisable. Options vest 1/3 per year.
Michael J. Farrell, Chief Executive Officer
2024-07-09